Security key
156944100
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 1,242,051
- Total 13F value
- $88,288,349
- Share change
- -112,327
- SEC-reported price per share
- $71.05
- Number of holders
- 37
- Value change
- -$7,936,209
- Number of buys
- 18
- Number of sells
- 14
- Shares outstanding
- 88,583,765
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
37
Top holders
10
CGON full security history
Ownership snapshot
Full 13F holder table
CG Oncology, Inc. SEC filings
CG Oncology, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 156944100
Recent filing periods:
Ownership snapshot
Top reported holders of CGON - CG Oncology, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Decheng Capital Global Li...
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 8.4%
13D/G row: Decheng Capital Global Life Sciences Fund IV, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Decheng Capital Global Life Sciences Fund IV, L.P. leads the comparable SEC ownership view at 8.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Decheng Capital Global Life Sciences Fund IV, L.P.'s linked filing trail.
Comparable ownership
Top 5
Decheng Capital Global Life Scien...
8.4%
RTW INVESTMENTS, LP
8.3%
T. Rowe Price Investment Manageme...
8%
WELLINGTON MANAGEMENT GROUP LLP
7.2%
BlackRock, Inc.
6.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. |
13D/G
3/4/5
Xiangmin Cui · 10%+ Owner
|
8.4%
|
$178,215,582
6,371,669 shares
|
$0 | 31 Dec 2024 |
| RTW INVESTMENTS, LP |
13D/G
13F
Company
|
8.3%
|
$472,871,502
6,984,808 shares
|
$0 | 31 Mar 2026 |
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
8%
|
$454,970,335
6,720,389 shares
|
$0 | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
Company
|
7.2%
from 13D/G
|
$363,524,981
5,371,232 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
6.8%
|
$427,983,601
6,023,696 shares
|
$0 | 30 Jun 2026 |
| Longitude Capital Partners IV, LLC |
13D/G
Patrick G. Enright
|
6%
|
$121,032,477
4,662,268 shares
|
$0 | 11 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
37
Shares
1,242,051
Rows available
37
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
233
Q2 2026 holders
37
Holder diff
-196
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend